• September 27, 2020

Polyneuron Extends Series A to CHF 36.5 Million with Additional CHF 14 Million - Odessa American: Business

e-Edition Subscribe

Polyneuron Extends Series A to CHF 36.5 Million with Additional CHF 14 Million

Print
Font Size:
Default font size
Larger font size

Posted: Wednesday, September 16, 2020 12:30 am | Updated: 12:47 am, Wed Sep 16, 2020.

BASEL, Switzerland--(BUSINESS WIRE)--Sep 16, 2020--

Polyneuron Pharmaceuticals AG, a clinical stage developer of a new class of antigen-specific polymers for the treatment of patients with serious autoimmune diseases, today announced a CHF 14 million extension of the Series A, bringing the total to CHF 36.5 million. HBM Healthcare Investments has joined the consortium of investors in the Series A, led by Sofinnova Partners, and which included New Enterprise Associates (NEA) and other private investors.

Polyneuron will use the proceeds to advance its lead product candidate PN-1007, a potential treatment for anti-MAG neuropathy, a serious nervous system disease with a high unmet medical need, through Phase I/IIa clinical development. Clinical studies with PN-1007 in patients are scheduled to begin before the end of 2020. The funding will also progress a second program, PN-1018, to the clinical trial application (CTA) approval stage. PN-1018 is being studied in Guillain-Barré Syndrome and Multifocal Motor Neuropathy. Polyneuron will also use the proceeds to accelerate preclinical development of its Antibody-Catch™ product portfolio in new indications, with a focus on antibody-mediated renal and hematological diseases.

“The interest from investors since the first closing has been phenomenal, so we decided to extend the Series A. We would like to welcome HBM Healthcare Investments to the consortium as part of that extension,” said Ruben Herrendorff, Ph.D., CEO and co-founder of Polyneuron. “The additional funds will enable us to take PN-1007 through Phase IIa and bring a second program, PN-1018, to the clinic, a great achievement for the whole Polyneuron team!”

Concurrent with the financing Dr Emil Bujak from HBM Healthcare Investments has been appointed to the Board of Directors.

“Polyneuron’s approach, using antigen-specific polymers to target and eliminate the pathological antibodies causing serious autoimmune diseases with a high unmet medical need, is unique and one we believe could resonate well in these difficult to treat diseases,” said Dr Bujak.

About HBM Healthcare Investments

HBM Healthcare Investments invests in the healthcare sector. The Company holds and manages an international portfolio of promising companies in the human medicine, biotechnology, medical technology and diagnostics sectors and related areas. Many of these companies have their lead products already available on the market or at an advanced stage of development. The portfolio companies are closely tracked and actively guided in their strategic direction. This is what makes HBM Healthcare Investments an interesting alternative to investments in big pharma and biotechnology companies. HBM Healthcare Investments has an international shareholder base and is listed on SIX Swiss Exchange (ticker: HBMN).

About Polyneuron Pharmaceuticals

Polyneuron Pharmaceuticals is pioneering a novel therapeutic approach for the effective and safe treatment of antibody-mediated immune diseases. The company’s Antibody-Catch™ technology platform enables the chemical design of injectable polymers that are able to selectively eliminate pathological antibodies in an antigen-specific manner, while leaving the rest of the immune system intact. Polyneuron was founded as a University of Basel, Department of Pharmaceutical Sciences, spin-off in 2014 by Dr. Ruben Herrendorff (CEO), Dr. Pascal Hänggi (CSO), Prof. Beat Ernst and Prof. Dr. med. Andreas J. Steck. The company is headquartered at the Stücki Park in Basel, Switzerland. More information can be found at http://www.polyneuron.com/.

Disclaimer

This press release contains forward-looking statements which are based on current assumptions and forecasts of the Polyneuron management. Known and unknown risks, uncertainties, and other factors could lead to material differences between the forward-looking statements made here and the actual development, in particular Polyneuron's clinical trial timelines, financial situation, and performance. Readers are cautioned not to put undue reliance on forward-looking statements, which speak only of the date of this communication. Polyneuron disclaims any intention or obligation to update and revise any forward-looking statements, whether as a result of new information, future events or otherwise.

View source version on businesswire.com:https://www.businesswire.com/news/home/20200915006184/en/

CONTACT: Polyneuron Pharmaceuticals

Dr. Ruben Herrendorff

+41 61 638 23 23

info@polyneuron.comHalsin Partners(media)

Mike Sinclair

+44 20 7318 2955

msinclair@halsin.com

KEYWORD: SWITZERLAND EUROPE

INDUSTRY KEYWORD: BIOTECHNOLOGY PHARMACEUTICAL HEALTH CLINICAL TRIALS

SOURCE: Polyneuron Pharmaceuticals AG

Copyright Business Wire 2020.

PUB: 09/16/2020 01:30 AM/DISC: 09/16/2020 01:30 AM

http://www.businesswire.com/news/home/20200915006184/en

© 2020 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Odessa, TX

Current Conditions

Sunny
102°
Humidity: 7%
Winds: WNW at 16mph
Feels Like: 102°

Your Extended Forecast

Tomorrow

weather
High 103°/Low 57°
Windy, partly cloudy. Lows overnight in the upper 50s.

monday

weather
High 74°/Low 46°
Partly cloudy. Highs in the mid 70s and lows in the mid 40s.

tuesday

weather
High 80°/Low 52°
Abundant sunshine. Highs in the low 80s and lows in the low 50s.
Online Features

Pet Central

pets

Having a pet is a lot of responsibility, and we’ll help by giving you lots of tips and tricks! More >>

Fitness

Fitness

Our fitness articles will help teach you how to work out with gym- and home-based exercises. More >>

Crosswords

Crosswords

Enjoy the crosswords challenge in our free daily puzzles, from the harder Sunday crossword to the quicker daily. More >>

Sudoku

Sudoku

Every Sudoku has a unique solution that can be reached logically. Enter numbers into the blank spaces so that each row, column and 3x3 box contains the numbers 1 to 9. More >>




  • ALL-ACCESS: Subscribe to our e-edition and premium website at myoaoa.com.
    You can read your daily newspaper without taking a walk to the driveway.
    Look back at yesterday's newspaper, or issues from months ago with our archive feature.
    Call circulation at 432-337-7314 to sign up today.